GlassScriptPhysician profile
Michael J Richard
NPI 1669434197
$112,573.00
in general payments reported to CMS, 2019-2025
11 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $3,024 · 2021: $5,131 · 2022: $28K · 2023: $19K · 2024: $33K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Honoraria: $15K · Consulting Fee: $6,300 · Travel and Lodging: $4,902 · Food and Beverage: $4,137 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,150.00 |
| Honoraria | $15,493.75 |
| Consulting Fee | $6,300.00 |
| Travel and Lodging | $4,902.31 |
| Food and Beverage | $4,137.28 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56,472.33 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $54,453.74 | 2020-2023 | Tepezza |
| Abbvie INC. | $576.16 | 2023-2025 | |
| Allergan, INC. | $358.80 | 2019-2022 | |
| Galderma Laboratories, L.P. | $325.21 | 2019-2023 | |
| Revance Therapeutics, INC. | $164.59 | 2024-2025 | Daxxify |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.99 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $55.34 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $32.62 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $19.22 | 2025 | |
| Argenx US, INC. | $15.00 | 2025 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Richard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.